In a letter to healthcare providers, the US FDA summarized a recent evaluation of a postapproval study of the Abiomed Impella RP system. In clinical trials, 73% of patients survived 30 days after device explant, hospital discharge, or to definitive intervention. In the postapproval study, just over 17% of patients met this goal.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Postmarket Experience With HeartMate 3 Left Ventricular Assist Device: 30-Day Outcomes From the ELEVATE Registry
January 30, 2019
Garbade and colleagues compared outcomes reported during the European Conformity (CE) Mark clinical trial of the HeartMate 3 left ventricular assist device (LVAD) to outcomes for patients treated since the device came to market.
Right Ventricular Pulmonary Coupling as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
January 18, 2019
A good attempt to shed some light into the somewhat challenging concept of heart failure with preserved ejection fraction, on the occasion of a small randomized controlled trial on albuterol.
January 17, 2019
A succinct handy comment on a small series of left ventricular assist devices (LVAD) that is quite useful for a fast read on LVAD for surgeons and nonsurgeons.
December 26, 2018
A randomized controlled trial coauthored by the Editor-in-Chief of the host periodical on the risk management of multivessel diabetic coronopathy.
“Respect When You Can, Resect When You Should”: A Realistic Approach to Posterior Leaflet Mitral Valve Repair
December 6, 2018
Gilles Dreyfus and colleagues share a decade of mitral reconstruction for degenerative posterior leaflet pathology in Harefield and Monaco (38 per year was the formidable average). The supplementary video is of particular educational value for the mitral surgeon and the cardiologist/TOE (TEE) specialist.
β-Adrenergic Agonist Albuterol Improves Pulmonary Vascular Reserve in Heart Failure With Preserved Ejection Fraction: A Randomized Controlled Trial
November 9, 2018
Interesting small randomized controlled trial that will definitely be widely discussed.
Six-Month Outcomes After Treatment of Advanced Heart Failure With a Full Magnetically Levitated Continuous Flow Left Ventricular Assist Device: Report From the ELEVATE Registry
October 23, 2018
A post-market study (ELEVATE registry) of the fully magnetically levitated continuous flow HeartMate III left ventricular assist device (LVAD) found no pump thrombosis in 463 patients in Europe and Kazakhstan.
October 23, 2018
This video demonstrates a valve replacement surgery for a 55-year-old woman who presented with carcinoid heart disease caused by a primary ovarian carcinoid tumor.
Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy
October 12, 2018
The authors of this paper investigated the efficacy and safety of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) in 15 patients with hypertophic cardiomyopathy (HOCM). At six months, they found significant reductions in peak left ventricular outflow tract gradients and intraventricular septal thickness.